67 Protein Therapies Companies - Worldwide
Search through all Protein Therapies companies with powerful filtering options
Company Name | Location | About |
|---|---|---|
Seattle, Washington, United States | A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/ | |
Boston, Massachusetts, United States | Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies. | |
Taipei, Songshan 105, TW | Allgenesis is a privately-held, clinical stage ophthalmology company based in Taiwan. The company is focused on novel multi-specific fusion proteins for treating diabetic macular edema and wet-age-related macular degeneration; and small molecule eye drops for dry eye and pterygium diseases. | |
La Jolla, California, United States of America | Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient’s own immune system by targeting the ß and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. Ambrx Biopharma Inc. has collaborations with various pharmaceutical companies, which include Bristol Myers Squibb Company; AbbVie Inc.; Astellas Pharma Inc.; and Elanco Animal Health. The company was founded in 2003 and is based in La Jolla, California. | |
Seattle, WA | Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines. | |
Boston, Massachusetts, US | Asimov's mission is to advance humanity's ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform from cells to software to design and manufacture next-generation therapeutics, including cell & gene therapies, through a combination of products, services, & collaborations. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million. | |
San Diego, California, United States | aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. | |
San Fransisco, US | Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit. | |
Durham, North Carolina, United States of America | BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices around the world. As world leaders in structure-guided drug design, we draw on the strengths and expertise of all our colleagues—from those of us in the field or behind the scenes in our labs, to others based in home offices and around the globe. To view our LinkedIn community guidelines, please visit bit.ly/BCRXGuidelines. | |
Berkeley, California, United States | Biomonadic is an early stage techbio startup leveraging AI and IoT to resolve critical supply chain bottlenecks affecting the cell and gene therapy (CGT). They are creating a next generation AI empowered data platform for biotech manufacturing, leveraging reinforcement learning and LLMs to augment their capabilities. | |
Uiwang-si, South Korea | BMI KOREA: A DYNAMICALLY-GROWING BIOPHARMACEUTICAL COMPANY, ALWAYS CHALLENGING FOR HEALTHY LIFE OF HUMAN-BEING. BMI is a pharmaceutical and biotechnology company based in South Korea that focuses on development and commercialization of new medicines (incl. biologics) and medical devices. BMI started to operate in 2005, and for more than a decade it has been growing with successful development of new medicines and biologics based on its own novel technologies and know-hows. BMI has specialized in sterile formulation and has developed many products such as HA, PN, PDRN and Botulinum Toxin etc. One of main BMI’s assets is “Hyaluronidase”. BMI has led the market over the last 10 years with two formulations: (A liquid sterile-brand: “Hirax® and a lyophilized sterile power vial- brand: “BM Hylunidase ®”). With these experiences and expertise, BMI has recently developed new generation of it, “Recombinant Hyaluronidase” which is well-known to be used for changing monoclonal antibody’s formulation from IV to SC. On top of that, BMI provides integrated CDMO services to help other pharmaceuticals and biotech companies develop and commercialize medicines. With the most advanced cGMP facilities and R&D center in JEJU and OSONG, BMI can deliver the highly qualified DS, DP and ensure partners’ success to IND, NDA and BLA. Full of speed and customer tailored flexibility are the main strengths. For more information, please visit our website below: www.bmikr.co.kr | |
Boulder, Colorado, United States | Bolder BioTechnology has a diversified pipeline of proprietary, long-acting human protein pharmaceuticals that include potential treatments for hematological and endocrine disorders, cancer supportive care, and orphan genetic diseases. | |
Seattle, Washington, United States | Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines. | |
Boston, Massachusetts, United States | BrickBio's engineered RNA and protein-chemistry platform technology enables custom tailoring of any protein with homogenous, site-specific and site-selective bioconjugation modifications, enabling novel classes of biologics with superior therapeutic windows and characteristics such as half-life, dosage, and efficacy. Having validated its precise and unrestricted conjugation capabilities through pharmaceutical co-development partnerships, the company is building its internal oncology and immunology pipeline by creating unique antibody and bispecific-conjugates while additionally pioneering spatial protein assembly for Precise Protein Origami™. | |
St. Louis, Missouri, United States | Canopy Biosciences, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our proprietary technology ChipCytometry™ is a quantitative multiplex immunofluorescence imaging method for the spatial analysis of complex tissues and mapping of cell populations with single-cell resolution. Supported by Canopy Spatial Services™ with our CLIA-certified laboratory, we provide a unique collection of spatial and single-cell technologies that accelerate the understanding of cellular diversity and interaction. Learn more at CanopyBiosciences.com. | |
South San Francisco, California, United States | Culture is your bioreactor lab, in the cloud. We help scientists accelerate bioprocess development with our high-throughput bioreactor cloud lab. You design your experiment, and we execute the experiment in our lab using our 250mL bioreactors. We take care of the high-quality execution so that you can focus on developing processes. While your experiment runs in our lab, you can monitor and analyze your data in real time using our online dashboard. With Culture, get faster insights to make better, data-driven decisions. | |
Graz, Austria | Cycuria Therapeutics is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and overall physiology. This enables durable efficacy without dose-limiting toxicity, as demonstrated in preclinical animal models and patient-derived disease models. By combining excellent tolerability with long-lasting efficacy, our novel therapeutic strategy aims to address significant unmet needs in cancer treatment, offering a new solution where conventional therapies have fallen short. | |
Vacaville, California, United States | Polaris Pharmaceuticals, is a biopharmaceutical development and manufacturing organization (CDMO) specializing in biologics derived from microbial systems. We have manufactured clinical material for trials in the United States, Europe, China, Taiwan, Australia, and Korea. Polaris Pharma offers a comprehensive range of process and analytical development and high-quality cGMP pre-clinical and clinical manufacturing services. We offer services for the following: • Process Development • Master and Working Cell Bank Propagation • Pre-Clinical/Clinical Manufacturing • QC Method Development • In Process Testing • Release Testing • Stability Storage and Testing • Availability to provide high purity WFI and PW • Custom Buffer and Media Manufacturing • Contract Filling, Labeling, Inspection • Microbial Based Fermentation Products | |
Suzhou, China | Eluminex Biosciences is a clinical-stage biotechnology company focused on development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases. | |
La Jolla, California, United States | Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics. | |
330 north wabash avenue, chicago, illinois, united states | Evozyne designs novel protein therapeutics to solve previously unaddressable patient needs. | |
Haverhill, Suffolk, United Kingdom | Getting genetic syntax right. With precise use of genetic grammar in transgenic design, ExpressionEdits unlocks the capacity to make proteins previously beyond reach. | |
Boston, Massachusetts, United States | Fable Therapeutics Inc. was founded with a conviction to revolutionize drug discovery through the purposeful integration of AI techniques. Our cross-functional team of ML scientists and drug hunters collaborate to design novel medicines with expanded therapeutic potential. With this passion and vision, we’re designing the future of drug discovery. | |
Cambridge, Massachusetts, United States | Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics. | |
Somerville, Massachusetts, United States | Generate:Biomedicines is a new kind of therapeutics company—existing at the intersection of machine learning, biological engineering, and medicine—pioneering generative biology to create breakthrough medicines. Through The Generate Platform, we are able to expand the breadth of technical possibilities in order to fundamentally change the way medicines are made. | |
700 main st, cambridge, massachusetts, united states, 02139-3543 | Gensaic is spearheading the development of multi-functional proteins for the dimensional delivery of therapeutics. Gensaic's mission is to decode the language of dimensional delivery: delivery with precision at the tissue, cell and subcellular dimensions. The team is writing the anthology of multi-functional delivery proteins with the FORGE platform, combining generative protein modeling and in-vivo protein evolution. | |
Glasgow, Scotland, United Kingdom | Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens. | |
Pagliuca Harvard Life Lab, 127 Western Ave., Boston, MA 02134, US | GRO Biosciences transforms protein therapeutics with new amino acid building blocks to treat incurable diseases. | |
Seattle, Washington, United States | Ice Bear Therapeutics SPC is a social purpose company based in Seattle, WA, founded 2021, with the mission of bringing affordable insulin to patients with type 1 or type 2 diabetes. | |
Yuseong-gu, Daejeon, South Korea | At ILIAS Biologics, we dedicate ourselves to the paradigm-shifting advances in human medicine. We are specialized in developing engineered exosomes by loading large therapeutic payloads inside exosomes via our proprietary platform technology, EXPLOR®. By harnessing the power of our engineered exosomes, we can deliver therapeutic proteins to the undruggable intracellular pathways to treat life-threatening and hard-to-treat rare diseases. With a strong belief and the power of open innovation, we are expanding our global network of research and business alliances to maximize our potential in the development of the novel exosome platform technology. | |
London, United Kingdom | Intract Pharma is a biotechnology company innovating in the field of oral delivery of complex proteins such as monoclonal antibodies with a special focus on treatment of gastrointestinal and systemic immune-mediated inflammatory diseases. Intract is applying it’s Phloral™ and Soteria™ technology platform for precision delivery of proteins to the colon for local tissue and systemic immunomodulation. Our vision is to transform care for millions of patients suffering from chronic diseases by converting their potent injectable biologic medicines into safe, effective and convenient take-at-home pills. | |
Palo Alto, California, United States | Juvena Therapeutics is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions. | |
Rehovot, Israel | Kamada is a growing commercial-stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions. The company is a leader in the specialty plasma-derived field focused on diseases with limited treatment alternatives, with 6 FDA-approved products selling in over 30 countries. The company is advancing an innovative development pipeline targeting areas of significant unmet medical need. | |
201.3 Building B, Biscuit Factory, 100 Drummond Road, London SE16 4DG, England, United Kingdom | LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Their mission is to accelerate the discovery of next-generation therapeutic antibodies that have been designed for maximum potential. They are headquartered in London and their core technology platform, EVA™, enables the development of novel protein therapeutics. | |
Shenzhen, China | Shenzhen Liying Biotechnology Co., Ltd. is a synthetic biology company based on the foundation of structural biology and cutting-edge artificial intelligence computation. We specialize in protein design and modification, providing high-quality and efficient research and development services for various protein applications, as well as the synthesis of protein materials. The company’s core technology founders and team members have over a decade of experience studying in the UK, with deep expertise in protein structure and function cultivated at top international universities and research institutions such as the University of Oxford, the University of Cambridge, and the Francis Crick Institution. They possess comprehensive technical workflows for advanced protein performance optimization and design that is internationally recognized. We have assembled a scientific advisory team at the Nobel Prize and Royal Academy Fellow level, as well as experts of high caliber from both domestic and overseas talent pools. Additionally, they have established extensive connections in industry, policy, and resources through the Chinese Central Organization Department’s Thousand Talents Program. | |
Seattle, Washington, United States | Lumen Bio is a clinical-stage biotechnology company developing topically and mucosally delivered biologic drugs to treat and prevent highly prevalent diseases. | |
Boston, Massachusetts | Manifold Bio is a therapeutics company with an unprecedented advantage in engineering precision biologics. We have developed the world’s first high-throughput in vivo drug design platform, enabled by a novel protein barcoding technology and other innovations at the interface of molecular biology and compute. Our mission is to make the best life-saving drugs available to patients as quickly as possible. We’ve brought together a team with unique expertise in library-guided protein engineering combining DNA synthesis, sequencing, and advanced bioinformatics and machine learning. We’re growing and we’re looking for those who are excited about the potential of our novel approach to engineering biology. | |
Cambridge, United Kingdom | Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins. | |
Waltham, Massachusetts, United States | Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now. | |
Zurich, Switzerland | Nerai Bio is a biotech startup pioneering ultra-specific genome editing technologies to treat genetic diseases. Using their AI-driven MORPHEME platform, they engineer novel gene-editing proteins that can precisely target and correct DNA at any location, addressing a broader range of genetic mutations than existing tools like CRISPR. Their lead therapeutic candidates focus on severe liver disorders, aiming to provide a single, permanent cure for conditions currently treated with lifelong care. Recently, Nerai Bio secured CHF 150,000 from Venture Kick to advance business development, preclinical validation studies, and partnerships. | |
Sydney, Australia | NeuClone is a clinical stage biopharmaceutical company exclusively developing and commercialising high quality biosimilar products. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at the scale and price to meet demand in both new and established markets globally. NeuClone is differentiated by our deep and unmatched pipeline, as well as our Right From the Start® approach where we continually confirm biosimilarity at the earliest stages and throughout development. | |
Boston, MA | At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine. In response to recent recruitment fraud, visit our Careers page to verify all job opportunities and read our guidance on this topic: https://odysseytx.com/careers/ | |
Seattle, Washington, United States of America | Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. | |
Cambridge, Massachusetts, United States | Orbital Therapeutics is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of RNA-based medicines to treat disease in humans. | |
barcelona, catalonia, spain | Orikine Bio is a pioneering biotech company dedicated to advancing the field of engineered cytokines with unparalleled biological features for the treatment of immune-mediated diseases. Our core mission is to unlock the untapped potential of cytokines, enabling us to offer transformative therapies that have the power to reshape the lives of patients around the globe. | |
2641 Osprey Vista Way UT Research Park | At Orio Therapeutics, our mission is to save lives by making the regenerative medicine dream accessible and a wide-spread reality. We are dedicated to developing novel regenerative drugs with increased efficacy and reduced side-effects, using cutting-edge targeted drug-delivery technologies to create novel therapeutic proteins. Notably, we strive to demonstrate that efficient drug delivery technologies are not confined to the development of complex devices and drug carriers but can be achieved based on clever molecular designs. We aim to initially validate our program pipeline through the development of a therapeutic molecule for myocardial infarction that has the potential to change the lives of patients following myocardial infarction by enabling faster recovery time and improved heart function. | |
Cambridge, MA | Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics or SMThs, designed to address complex diseases by targeting rare combinations of proteins that work together. Using its proprietary Locksmith platform, the company is advancing programs across multiple therapeutic areas to create new options for patients with common, hard-to-treat conditions. | |
Barcelona, Catalonia | Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research on Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. | |
Boston, Massachusetts, United States of America | Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for rare and more prevalent neurological disorders. We share a common vision of reshaping the human condition into a more freeing and fulfilled existence by developing high impact medicines for patients and families affected by and living with complex brain disorders. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. | |
119 Spadina Ave, 304, Toronto, Ontario M5V 2L1, CA | ProteinQure is a biotech company focused on the design of novel exotic peptides with broad therapeutic applications. Powered by atomic-level simulations and artificial intelligence, we design dynamic peptides that take drugs straight to their target – outperforming other treatment delivery systems. By daring to deliver therapeutics in a novel way we are changing the game for drug development and bringing hope to patients with previously untreatable diseases. At ProteinQure, we pride ourselves on our unique, diverse and cross-disciplinary team that brings together experts from experimental & computational biology, machine learning and software engineering. | |
Geneva, Switzerland | Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland. | |
Headquarters address not available | RenBio was founded on the principle that the remarkable medical benefits of antibody therapeutics should be available to everyone, and was named one of DARPA’s “Biotech Startups of the Future” one year after opening its operations. The company was co-founded by David D. Ho, MD (Time magazine's "Man of the Year" in 1996 and recipient of the Presidential Citizens Medal) and Yaoxing Huang, PhD, visionary scientists affiliated with the Aaron Diamond AIDS Research Center and Professors at Columbia University Medical Center. RenBio is backed by the Bill & Melinda Gates Foundation, DARPA, and a syndicate of private investors, and is headquartered at the Alexandria Center® for Life Science in New York City. | |
Miami, Florida, United States | Resolve Therapeutics is a biotechnology company developing an exciting new biologic compound for the treatment of lupus that inhibits a key upstream step in the interferon cascade. The company is based on technology and compounds exclusively licensed from the University of Washington. The company will develop these compounds through early clinical testing and partner with a pharmaceutical company for late stage clinical development and commercialization. | |
1-9-10 Horidome-cho, Nihonbashi, Chuo-ku, Tokyo, JP | RevolKa is a pioneer of next-generation protein engineering. We are committed to the discovery and development of innovative proteins by leveraging our proprietary artificial intelligence-integrated directed protein evolution technology, called aiProtein®. RevolKa is open to research collaboration opportunities with partners and also co-development of our internal assets. About aiProtein® RevolKa innovatively integrated directed protein evolution with the transformative digital technology, artificial intelligence (AI) to create a proprietary powerful protein engineering technology, called aiProtein®. aiProtein® remarkably accelerates directed protein evolution and enables to create unprecedented engineered proteins. This platform is a robust solution for biologics engineering, for example, to address issues in developability and manufacturability of therapeutic antibodies. aiProtein® enables multi-dimensional simultaneous engineering for protein properties, such as efficacy, affinity, physicochemical properties, immunogenicity, species cross-reactivity, and so on. | |
2 Hamayan st, Modin, 7177871, IL | Silexion Therapeutics is a pioneering clinical-stage oncology-focused biotechnology company engaged in discovering and developing proprietary treatments for KRAS-driven cancers. The company's platform technology is addressing difficult-to-treat solid tumors. Silexion's lead product candidate, SIL-204, consists of locally administered small interfering RNAs, or siRNA, in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients combined with standard-of-care chemotherapy. SIL-204 is a siRNA product candidate following Phase 1 and Phase 2 clinical trials with Silexion's first-generation siG12D-LODER, also referred to as LODER™. Results from the LODER™ Phase 2 clinical trial showed a trend for differences between treatment groups with the LODER arm suggesting an overall survival advantage of 9.3 months. Silexion commitment to Pushing the boundaries of therapeutic advancements in the field of oncology is focused on its second-generation microparticle delivery system, SIL-204 a newly formulated product that will improve clinical efficacy. Silexion plans to conduct a Phase 2/3 trial of SIL-204 in locally advanced pancreatic cancer patients that harbor the KRAS G12D and G12V mutations. Silexion Therapeutics Ltd. is headquartered in Israel and partnered with well known GMP compliant siRNA facility, LGC Axolabs group located in Petaluma California, and worldwide experts extended-release formulation facility, EVONIK Corporation located in Birmingham, Alabama to upscale manufacturing. | |
3300 Plymouth Blvd., PO Box 47099, Plymouth, Minnesota 55447, US | SilkTech Biopharmaceuticals develops silk-based anti-inflammatory therapies. Our lead indication is in Dry Eye Disease, an inflammatory based chronic condition. | |
Cambridge, Massachusetts, United States of America | SmartPharm Therapeutics, now a subsidiary of Sorrento Therapeutics, is a gene therapy company applying the next generation of non-viral DNA and RNA technologies to treat serious human diseases. Founded with the vision of producing “Biologics from Within,” SmartPharm is focused on bringing together unique technology and developmental capabilities for the treatment of rare diseases including lysosomal storage disorders. SmartPharm Therapeutics is a second-generation gene-encoded therapeutics company that has benefited from the first decades of learning in gene therapy development to produce an evolved therapeutic platform. We integrate these insights with key technologies and engineering capabilities to enable us to produce optimal gene-encoded therapeutics for patients. | |
San Diego, California, United States | Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. In addition, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease. More information on Stemedica may be found at www.stemedica.com. | |
Seattle, Washington, United States | Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics. As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery: - Developing internal programs against previously undruggable gene regulators in cancers with poor standard of care - Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs | |
Plaza Cein, Noáin, Chartered Community of Navarre 31110, ES | Telum Therapeutics SL is a global drug discovery biotechnology company specializing in the use of Innovative Phage Lytic Proteins as antibiotics. | |
Frederick, Maryland, United States | Developed a computational platform that converts recombinant proteins intomaterial-binding variants that can be used to coat implants, devices, and injectable carriers. | |
TherapyX Headquarters, Buffalo, New York, United States | TherapyX Inc. is changing the future of pharmaceuticals using revolutionary technology. They encapsulate large biological molecules in an orally ingestible form, allowing these molecules to remain fully intact. | |
Copenhagen, Denmark | Tribune Therapeutics is a biotechnology company advancing novel medicines to treat fibrosis, regardless of the cause, tissue or diagnosis. The company was founded on groundbreaking structural insights into the CCN family of proteins, key drivers of scar formation that have historically been difficult to comprehensively target. Tribune is advancing multiple programs, including CCN5 mimic TRX-44. | |
Columbus, Ohio, United States | We are a US biotech company focused on restoring cell health and resilience, with profound initial indications for the treatment of cancers and rare diseases, the protection of multiple organ injuries, and the effective reversal of aging. We are looking for investors, development partners, or licensees. Interested parties please contact us for further information and discussions. | |
Dallas, Texas | Venturis Therapeutics, Inc is a clinical stage bio-pharmaceutical company advancing novel therapeutics utilizing regenerative medicine to address diseases such as diabetic foot ulcers (DFU), severe ischemic heart disease, and peripheral artery disease (PAD) by regrowing the microvascular circulation (angiogenesis) | |
Scarborough, Maine, US | ||
seattle, washington, united states | ZipBio is a biotech startup revolutionizing AI drug discovery with our cutting-edge protein design and drug discovery platform. We specialize in compressing biology to accelerate therapeutic innovation. |